Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TAS1553是一种高效的可口服蛋白质-蛋白质相互作用(PPI)抑制剂,其IC50值为0.0396 μM。TAS1553 有效地阻碍DNA复制并减少细胞内dATP池。此外,TAS1553诱导凋亡,[1]使其在癌症研究中极具价值。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 983 | 现货 | ||
2 mg | ¥ 1,460 | 现货 | ||
5 mg | ¥ 2,490 | 现货 | ||
10 mg | ¥ 3,730 | 现货 | ||
25 mg | ¥ 5,970 | 现货 | ||
50 mg | ¥ 8,420 | 现货 | ||
100 mg | ¥ 11,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,650 | 现货 |
产品描述 | TAS1553 is a highly effective, orally bioavailable protein-protein interaction (PPI) inhibitor with an IC50 value of 0.0396 μM. It effectively hinders DNA replication and diminishes the intracellular dATP pool. Moreover, TAS1553 induces apoptosis, making it a valuable compound in cancer research [1]. |
体外活性 | TAS1553 (0.001-1 μM) dose-dependently inhibits the enzymatic activity of RNR [1]. TAS1553 (3 d) has anti-proliferative activity against both solid and hematological human cancer cell lines and the GI 50 values ranged from 0.228 to 4.15 μM [1]. TAS1553 (1-10 μM; 0-2 h; HCC38 and MV-4-11 cells) reduces intracellular dATP pool in a dose- and time-dependent manner, which is a critical metabolite for DNA replication [1]. TAS1553 (0-10 μM; 0-24 h; HCC38 and MV-4-11 cells) induces the replication stress and apoptosis in a dose- and time-dependent manner [1]. Western Blot Analysis [1] Cell Line: HCC38 and MV-4-11 cells Concentration: 0, 0.1, 0.3, 1, 3 and 10 μM Incubation Time: 0, 1, 2, 4, 8 and 24 hours Result: Increased the expression of Ser345, Ser4, Ser8 and Thr21 phosphorylation. Increaed the levels cleaved PARP and cleaved caspase-3. |
体内活性 | TAS1553 (25-200 mg/kg; p.o.; for 24 h; female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice) shows RNR inhibitory effect in vivo [1]. TAS1553 (50-200 mg/kg; p.o.; daily, for 15 d; female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice) has antitumor activity in vivo [1]. Animal Model: Female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice [1] Dosage: 25, 50, 100 and 200 mg/kg Administration: Oral administration; for 24hours Result: Reduces intracellular dATP pool and induces the replication stress and apoptosis. Animal Model: Female F344/NJcl-rnu/rnu rats and BALB/cAJcl-nu/nu mice [1] Dosage: 50, 100 and 200 mg/kg Administration: Oral administration; daily, for 15 days Result: Inhibited tumor growth in the treated group/control group (T/C) were 52.0 (50 mg/kg), 45.0 (100 mg/kg) and 29.4% (200 mg/kg), respectively. |
分子量 | 482.91 |
分子式 | C20H20ClFN4O5S |
CAS No. | 2166023-31-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (186.4 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0708 mL | 10.3539 mL | 20.7078 mL | 51.7695 mL |
5 mM | 0.4142 mL | 2.0708 mL | 4.1416 mL | 10.3539 mL | |
10 mM | 0.2071 mL | 1.0354 mL | 2.0708 mL | 5.1769 mL | |
20 mM | 0.1035 mL | 0.5177 mL | 1.0354 mL | 2.5885 mL | |
50 mM | 0.0414 mL | 0.2071 mL | 0.4142 mL | 1.0354 mL | |
100 mM | 0.0207 mL | 0.1035 mL | 0.2071 mL | 0.5177 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
TAS1553 2166023-31-8 Others TAS 1553 TAS-1553 Inhibitor inhibitor inhibit